Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Salt-Marsh plant extract help control cholesterol?

NCT ID NCT07559110

Disease control Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a dietary supplement made from halophyte plant extracts (like salicornia) and B vitamins can improve cholesterol levels in people recently diagnosed with dyslipidemia who do not yet need medication. About 250 participants will take the supplement or follow standard care for 3 months. The goal is to see if the supplement can safely lower cholesterol and other blood fats.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dietary supplement based on halophyte plant extracts (salicornia) and B vitamins
What this could lead to
If it works, this could offer a natural option to help manage cholesterol levels without prescription drugs.
What could go wrong
This is a small, early pilot study with only 250 participants, so results may not be conclusive. The supplement is not a substitute for medication and may have limited effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants aged 40 to 65 * Newly diagnosed dyslipidemia (two years) with SCORE ≥1 - \<5 (LDL 116 - \<190 mg/dL): Moderate Risk * No indication for pharmacological treatment in primary prevention. * Possibility of performing analytical controls at the beginning/end of the study. * Willingness and capacity to give informed consent. Exclusion Criteria: * Participants with vascular risk requiring pharmacological treatment or high/very high vascular risk. * Participants in secondary prevention. * Hyperthyroidism according to the researcher's criteria. * Taking vitamin B supplements and/or supplements containing polyphenols in the 30 days prior to the screening visit (at the researcher's discretion). * Serious illness with a life expectancy of less than three months. * Known allergies or intolerance to halophytic plants. * Pregnant or breastfeeding women. * Presence of active neoplastic disease. * Having participated in another clinical trial with medicines in the 30 days prior to the screening visit, or intending to do so during your participation in this study. * Regular consumption of halophyte plants. * Participants who, in the researcher's opinion, are not able to comply with the study protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dyslipidemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Dyslipidemias inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dyslipidemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital Virgen Macarena

    Seville, 41009, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.